Effects of Spray and Stretch on Postneedling Soreness and Sensitivity After Dry Needling of a Latent Myofascial Trigger Point.

This study has been completed.
Information provided by (Responsible Party):
CEU San Pablo University
ClinicalTrials.gov Identifier:
First received: May 27, 2012
Last updated: September 3, 2013
Last verified: September 2013

Pain after dry needling or injection in the muscle is a frequent secondary effect in the treatment of myofascial pain syndrome. In this trial spray and stretch technique is evaluated as a method to reduce this soreness. As well, the characteristics and the different factors that influence in this pain will be described.

Condition Intervention Phase
Pain After Dry Needling
Other: Spray and stretch
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single Blind (Investigator)
Primary Purpose: Treatment

Further study details as provided by CEU San Pablo University:

Primary Outcome Measures:
  • Pain [ Time Frame: 72 hours ] [ Designated as safety issue: No ]
    Visual analogue scale

Secondary Outcome Measures:
  • Pain [ Time Frame: 48 hours ] [ Designated as safety issue: No ]
    Pressure pain threshold

  • Psychological factors [ Time Frame: 72 hours after needling ] [ Designated as safety issue: No ]
    Symptom check list revised. SCL-90-r

Enrollment: 70
Study Start Date: March 2012
Primary Completion Date: April 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Spray and stretch Other: Spray and stretch
Physiotherapeutic technique which consist in stretching the muscle while a cold spray is applied on the skin.
No Intervention: Control


Ages Eligible for Study:   18 Years to 65 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Subjects presenting latent trigger points in the trapezius muscle

Exclusion Criteria:

  • Subjects with active trigger points or absence of trigger points.
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01608633

CEU San Pablo University
Madrid, Spain, 28668
Sponsors and Collaborators
CEU San Pablo University
  More Information

No publications provided

Responsible Party: CEU San Pablo University
ClinicalTrials.gov Identifier: NCT01608633     History of Changes
Other Study ID Numbers: CEU-001
Study First Received: May 27, 2012
Last Updated: September 3, 2013
Health Authority: Spain: Ethics Committee

ClinicalTrials.gov processed this record on April 14, 2014